Table 5.
Analysis of newly diagnosed and existing patients: Marginal effect for a $100 increase in copayment in initial coverage
| All specialty cancer therapy drugs | Specialty antineoplastics | |
|---|---|---|
| Newly diagnosed patients a (N=93,737) | ||
|
| ||
| Specialty cancer drug use | ||
| Ordinary least squares (OLS) | −0.027(0.026) | −0.022(0.017) |
| IV estimates; 2-state least squares (2SLS) | −0.046(0.042) | −0.025(0.024) |
| Specialty cancer drug spending among users | N=1,122 | N=840 |
| OLS | 272.48(604.55) | 471.68(495.22) |
| 2SLS | 302.79(897.11) | 218.16(784.39) |
|
| ||
| Existing patients (N=203,930) | ||
|
| ||
| Specialty cancer drug use | ||
| OLS | −0.043(0.025)* | −0.031(0.018)* |
| 2SLS | −0.079(0.032)** | −0.053(0.021)** |
| Specialty cancer drug spending among users | N=3,131 | N=2,721 |
| OLS | −559.17(308.34)* | −365.91(251.75) |
| 2SLS | −439.06(498.33) | −269.11(381.77) |
a
Newly diagnosed patients were defined as those with no cancer claim in the prior year (a one-year wash-out period). Standard errors (clustered within a plan) are in parentheses;
*
p < 0.10,
**
p < 0.05,
***
p < 0.01